Edrecolomab ELISA Kit
Edrecolomab ELISA Kit is a quantitative ELISA kit for detection of Edrecolomab.
Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.
Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.
| Supplier | Abbexa Ltd. |
|---|---|
| Product # | abx395087-96T |
| Pricing | 96 tests USD $942.5 |
| Tested Applications | ELISA |
| Test Range | 0.31 μg/ml - 5 μg/ml |
| CAS Number | 156586-89-9 |
| Availability | Shipped within 5-12 working days. |
| Dry Ice | No |
| Note |
|